

Patient-Focused Interactive Treatment Tool:

Key Information You Need to Know About Your Advanced Ovarian Cancer Diagnosis

The goal of the patient-focused interactive treatment tool (clinicaloptions.com/OvarianPatientTool) developed in partnership by Clinical Care Options and GRACE for patients with advanced ovarian cancer is to help you better understand your diagnosis and treatment options so that you can become partners with your oncology team in your cancer care.

To most effectively use the tool, it is recommended that you have as much information about your cancer as possible before you begin. If you do not have this information yet, you can ask your oncologist to help you fill out this checklist with useful questions about your cancer diagnosis.

You can then enter the specific information about your cancer into the tool by answering a series of multiple choice questions. Once all the information is entered, the tool will provide the treatment choices of 5 ovarian cancer experts according to the answers you choose.

- **What type of therapy are you and your oncologist considering?**

- ☐ Treatment for your newly diagnosed cancer (frontline therapy)
- ☐ Maintenance treatment after frontline therapy for newly diagnosed cancer
- ☐ Treatment for your cancer that has come back (second-line therapy for recurrent disease)
- ☐ Maintenance treatment after second-line therapy for cancer that came back

Please go to the matching section(s) below based on your answer to this question

If you are considering therapy for your newly diagnosed cancer (frontline therapy)

1. What type of ovarian cancer do you have?

- ☐ High-grade serous carcinoma, endometrioid carcinoma, carcinosarcoma
- ☐ Clear cell, mucinous, or low-grade serous carcinoma

2. Do you have hereditary ovarian cancer?

- ☐ No, I do not have a family history of cancer and my cancer is HRD negative
- ☐ Yes, my cancer is HRD positive, but I do not have a deleterious *BRCA* mutation
- ☐ Yes, I have a deleterious somatic or germline *BRCA* mutation

If you are considering maintenance treatment after frontline therapy

1. Do you have hereditary ovarian cancer?

- ☐ No, I do not have a family history of cancer and my cancer is HRD negative
- ☐ Yes, my cancer is HRD positive, but I do not have a deleterious *BRCA* mutation
- ☐ Yes, I have a deleterious somatic or germline *BRCA* mutation

2. What frontline chemotherapy did you receive?

- ☐ Platinum-based chemotherapy
- ☐ Platinum-based chemotherapy + bevacizumab (Avastin®)
- ☐ Platinum-based chemotherapy + PARP inhibitor (Zejula®, Lynparza®, or Rubraca®)

3. How did your cancer respond to frontline therapy?

- ☐ Complete response or partial response (CR or PR)
- ☐ I have stable disease (SD)
- ☐ I have progressive disease (PD)



If you are considering treatment for your cancer that has come back (second-line therapy)

1. Do you have hereditary ovarian cancer?

- ☐ No, I do not have a family history of cancer and my cancer is HRD negative
- ☐ Yes, my cancer is HRD positive, but I do not have a deleterious *BRCA* mutation
- ☐ Yes, I have a deleterious somatic or germline *BRCA* mutation

2. What frontline chemotherapy did you receive?

- ☐ Platinum-based chemotherapy
- ☐ Platinum-based chemotherapy + bevacizumab (Avastin®)
- ☐ Platinum-based chemotherapy + PARP inhibitor (Zejula®, Lynparza®, or Rubraca®)

3. How long was your cancer in remission after you received frontline therapy?

- ☐ Less than 6 months
- ☐ At least 6 months or longer

4. Are you eligible for platinum-based chemotherapy?

- ☐ Yes
- ☐ No

If you are considering maintenance treatment after second-line therapy

1. Do you have hereditary ovarian cancer?

- ☐ No, I do not have a family history of cancer and my cancer is HRD negative
- ☐ Yes, my cancer is HRD positive, but I do not have a deleterious *BRCA* mutation
- ☐ Yes, I have a deleterious somatic or germline *BRCA* mutation

2. What frontline chemotherapy did you receive?

- ☐ Platinum-based chemotherapy
- ☐ Platinum-based chemotherapy + bevacizumab (Avastin®)
- ☐ Nonplatinum chemotherapy
- ☐ Nonplatinum chemotherapy + bevacizumab (Avastin®)

3. How did your cancer respond to second-line therapy?

- ☐ Complete response or partial response (CR or PR)
- ☐ I have stable disease (SD)
- ☐ I have progressive disease (PD)

4. Have you ever received a PARP inhibitor (Zejula®, Lynparza®, or Rubraca®)?

- ☐ Yes
- ☐ No

